Behandlung der Immunbedingten Hämolytischen Anämien Beim Hund
World Small Animal Veterinary Association World Congress Proceedings, 2010
Philadelphia, PA, USA

Lesen Sie die englische Übersetzung: Treatment of Immune-Mediated Hemolytic Anemia

Immunbedingte hämolytische Anämien treten sehr häufig beim Hund auf, können primär (idiopathisch oder autoimmun) oder sekundär infolge einer Grundkrankheit (Infektion, Tumor, Arzneimittel) verursacht sein und gehen oft mit schweren Komlikationen einher. Die Diagnose bedarf des Nachweises von Hämolyse und einer Immunantwort die auf Erythrozyten gerichtet ist. Das heisst neben regenerativer Anämie, Ikterus und Hyperbilirubinurie müssen auch Autoagglutination, Sphärozytose und/oder ein positiver direkter Coombs-test nachgewiesen werden. Die Prognose ist sehr unsicher bis ungünstig zu stellen; die reportierte Mortalitätsrate schwankt zwischen 20-60% und ist insbesondere bei schwergradiger Anämie, Ikterus, Autoagglutination, Hypoproteinämie und Thrombosen schlecht. Bislang fehlt der direkte Nachweis einer effektiven Therapie der immunbedingte hämolytische Anämien, doch werden allgemein neben der Behandlung der Grundkrankheit, Rehydrierung, Transfusiontherapie und Immunosuppression und andere unterstützende Massnahmen durchgeführt. Obschon weitere Ausführungen unten auf Englisch beschrieben sind, wird dieser Vortrag auf Deutsch gehalten.

A diagnosis of Immune-mediated hemolytic anemia (IMHA) requires the documentation of red blood cell destruction and an immune process. While regenerative anemia, icterus, and hyperbilirubinuria are suggesting a hemolytic anemia, evidence of true autoagglutination, spherocytosis, and/or a positive direct Coombs' test are required to document immune destruction. The prognosis is highly variable ranging from 20% to over 60% mortality, severe anemia, icterus, hypoalbuminemia, and thrombosis are negative prognostic indicators. Because the severity of IMHA ranges from indolent to life-threatening disease, therapy has to be tailored for each patient and depends in part on whether the IMHA is primary or secondary in nature. Removal of the triggering agent or treatment of the underlying condition can bring the IMHA rapidly under control.

Restoration and maintenance of tissue perfusion with crystalloid fluids is important, even when it results in further lowering of the hematocrit. When severe anemia and a dropping hematocrit lead to signs of tissue hypoxia, packed red blood cell transfusions appear beneficial. The increased oxygen-carrying capacity provided by the transfused red blood cells may be sufficient to maintain the animal's hematocrit for a few days, while other treatment modalities have time to become effective. The notion that transfusions pose an increased hazard to animals with IMHA has been overemphasized and is not supported by retrospective clinical studies. However, the common occurrence of autoagglutination may make blood typing and crossmatching of a patient impossible. In these cases DEA 1.1-negative blood should be transfused. Additional blood types are being recognized which may be also important.

If compatible blood is not available, the bovine hemoglobin solution Oxyglobin may be administered and provides increased oxygen-carrying capacity and plasma expansion. The original FDA study documented the beneficial effects of Oxyglobin, whereas recent retrospective studies do not allow any conclusions. The future availability of Oxyglobin is in question as Biopure has ceased to exist. In contrast to blood and Oxyglobin, oxygen inhalation therapy is of little benefit, unless the animal is suffering form pulmonary disease such as pulmonary thromboemboli. Thanks to adequate transfusion support, animals with IMHA rarely die because of anemia, but because of secondary complications such as thromboemboli and infections.

The insufficient understanding of the pathogenesis, the generally guarded prognosis, the lack of good therapeutic trials, the serious drug side effects, and the high costs of intensive care greatly hamper the successful management of dogs with IMHA. The main goal of immunosuppressive therapy is to reduce phagocytosis, complement activation, and anti-erythrocytic antibody production. Glucocorticoids are the initial treatment of choice for canine and human IMHA. They interfere with both the expression and function of macrophage Fc receptors and thereby immediately impair the clearance of antibody-coated erythrocytes by the macrophage system. In addition glucocorticoids may reduce the degree of antibody binding and complement activation on erythrocytes, and only after weeks, diminish the production of autoantibodies. Thus, oral prednisolone at a dose of 1-2 mg/kg twice daily is the mainstay treatment. Alternatively, oral or parenteral dexamethasone at an equipotent dose of 0.6 mg/kg daily can be used, but is likely not more beneficial.

Additional immunosuppressive therapy is warranted when prednisone fails, only controls the disease at persistently high doses, or when it causes unacceptable side effects. They are generally used together with prednisone, but may eventually be used independently. Historically, cytotoxic drugs such as cyclophosphamide were added, however a small randomized study and several retrospective surveys failed to show any beneficial effects, but cyclophosphamide may be associated with greater morbidity and mortality in the acute management of IMHA. Retrospective studies and anecdotal reports with azathioprine, cyclosporine, danazol, mycophenolate, leflunomide, and human intravenous immunoglobulin indicate some efficacy and may be associated with fewer side effects, but controlled prospective clinical trials that document their efficacy are lacking. Finally, in refractory cases and whenever the spleen seems pathologically large splenectomy should be considered. This should not be performed when the animals are on more than glucocorticoids as these patients will be critically immunosuppressed post-splenectomy.

It should be noted that an apparent therapeutic response to immunosuppressive therapy is insufficient evidence for the diagnosis of IMHA. Response to therapy may be indicated by a hematocrit that rises or stabilizes, an appropriate reticulocytosis, diminished autoagglutination, and fewer spherocytes; these responses can be expected to be seen within days. The subsiding of autoagglutination would allow the performance of a direct Coombs' test and thereby permit the direct documentation of anti-erythrocytic antibodies. As glucocorticosteroid therapy is associated with well-known side effects, the initial dose will be tapered by reducing the amount by one-third every 7-14 days and moving toward an every other day therapy. In secondary IMHA with appropriate control of the underlying disease, the tapering can be accomplished more rapidly. Because of the potential of gastrointestinal ulceration by glucocorticosteroids, gastrointestinal protectants such as sucralfate may be considered. Because dogs with IMHA suffer from immune deregulation, which may have been triggered by an infection, and are treated with immunosuppressive agents, these patients are prone to experience infections; it is, therefore, prudent to administer preventative as well as therapeutic antibiotics to these dogs with IMHA on immunosuppressive therapy.

Thromboemboli and DIC are unique serious complications that greatly contribute to the morbidity and mortality of dogs with IMHA. Although the pathogenesis remains unknown, venipuncture, catheters, confinement, and glucocorticosteroids as well as other immunosuppressive agents may be contributing factors. Thus far, no study has documented any successful prevention and/or management protocol for these life-threatening hemostatic problems in canine IMHA. Predisposing factors should, whenever possible, be limited, and adequate perfusion and tissue oxygenation should be provided with fluids and transfusions or Oxyglobin. Generally, anticoagulation therapy is instituted after there is some evidence or suspicion of thromboemboli. Unfractionated Heparin (dose of 50-300U/kg subcutaneously every 6 hours or by continuous intravenous infusion) or Low Molecular Weight Heparin (LMWH; Dalteparin 150 IU/kg sc every 12 hours) are the most commonly used drugs and is used. The replacement of coagulation factors and antithrombin III has not been proven to be beneficial. Antiplatelet agents may also be used and for instance an ultralow dose of aspirin (0.5mg kg once daily) has been advocated by a couple of groups, but other studies question its efficacy. Other antithrombotic agents such as modern antithrombotic agents have been used occasionally, but their efficacy and safety remain also unproven.


Speaker Information
(click the speaker's name to view other papers and abstracts submitted by this speaker)

Philadelphia, PA, USA

MAIN : Hämatologie : Hämolytischen Anämie
Powered By VIN